Archive · 7 Oct 2026
India’s CDMO Sector Highlights Three Pharma Stocks to Watch
Pharmaceutical companies sometimes hire other companies to help develop and make medicines.
These businesses are called CDMOs.
The article says Indian CDMOs are getting more work as drugmakers diversify where they produce medicines.
It discusses Laurus Labs, Divi’s Laboratories and Akums Drugs and Pharma.
Each company reported recent business or financial developments.
Laurus reported higher revenue, while Divi’s reported higher income and profit compared with the year-earlier quarter.
Akums said its CDMO business helped drive growth.
The article also notes that companies are investing in new manufacturing capacity.
It cautions readers to check a company’s finances and risks before investing.
India’s CDMO sector is benefiting from supply-chain diversification, competitive costs and demand for more complex pharmaceutical manufacturing.
Laurus Labs reported Q1 FY27 revenue of Rs 20.26 billion, up 29%, with higher CDMO commercial supplies contributing to growth.
Divi’s Laboratories reported Q1 FY27 consolidated income of Rs 31.44 billion, while profit after tax rose to Rs 9.02 billion.
Akums Drugs and Pharma reported Q1 FY27 revenue growth of over 13% and EBITDA growth of more than 30%, led mainly by its CDMO business.
The article says investors should assess debt, returns, regulatory records, valuations, client retention and earnings quality; it is not a stock recommendation.
- Who
- Laurus Labs, Divi’s Laboratories and Akums Drugs and Pharma.
- What
- An overview of three Indian pharmaceutical CDMO stocks and their recent business and financial developments.
- When
- The article discusses Q1 FY27 results and, for Akums’ acquisition, an announcement made in July; the year of that July is not specified.
- Where
- India.
- Why
- The article presents the companies amid growth in India’s CDMO sector, which it links to supply-chain diversification and demand for higher-value manufacturing.
- Companies covered
- Laurus Labs, Divi’s Laboratories and Akums Drugs and Pharma
- Sector
- Pharmaceutical contract development and manufacturing organizations (CDMOs)
- Laurus Labs Q1 FY27 revenue
- Rs 20.26 billion, up 29%
- Divi’s Laboratories Q1 FY27 consolidated income
- Rs 31.44 billion, compared with Rs 25.29 billion in the corresponding quarter a year earlier
- Divi’s Laboratories Q1 FY27 profit after tax
- Rs 9.02 billion, compared with Rs 5.45 billion in the corresponding quarter a year earlier
- Akums Q1 FY27 growth
- Revenue grew by over 13% and EBITDA by more than 30%; the article says the CDMO segment primarily led growth.
- Investment caveat
- The article is informational, not a stock recommendation, and advises assessing fundamentals, regulatory records and valuation.